Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

748.01 -1.91 (-0.25%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
99 100 Next >
Eli Lilly Stock Jumps On Strong Earnings, Guidance As Zepbound, Mounjaro Sales Boom
Drug giant also raises guidance. Lilly stock soared. 
Via Investor's Business Daily
Bears Betting Against Nvidia And Eli Lilly For 'Easy Money,' Says Jim Cramer: 'Those Are The Two Keys To This Market And Don't You Know It'
Jim Cramer has issued a warning about the bearish pressure on NVIDIA Corp. and Eli Lilly and Co, stating that these two companies are crucial to the market's performance. 
Via Benzinga
Before the Bell: Eli Lilly Presents its Q2 Results
Before the Bell: Eli Lilly Presents its Q2 Results 
Via Chartmill
US Stocks Decline As SMCI's Margin Miss Brings Nvidia And Other AI Stocks Under Pressure: Investor Sentiment Remains In 'Extreme Fear' Zone
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Eli Lilly, US Foods And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
Decoding Eli Lilly's Options Activity: What's the Big Picture?
Via Benzinga
Should You Buy Eli Lilly Before Aug. 8?
There's reason to be optimistic about what's to come. 
Via The Motley Fool
Here's Why Eli Lilly Stock Dropped 12% Last Month
News from a competitor gave investors an unwelcome dose of reality. 
Via The Motley Fool
Eli Lilly: Bearish Signals Loom Over Weight Loss Stock Ahead Of Q2 Earnings
Eli Lilly (LLY) reports Q2 earnings on Thursday with expected EPS of $2.70 and $9.9B in revenues. Stock shows bearish trend but analysts predict 15% upside. 
Via Benzinga
What's Going On With Eli Lilly And Company Shares Wednesday?
Eli Lilly is anticipated to release earnings 2024 fiscal year earnings on Thursday before the market opens. 
Via Benzinga
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows
Via Investor Brand Network
Amgen's MariTide Weight Loss Potential: Stock Outlook
Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property Product Safety
How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings
Some investors may be eyeing potential gains from the company's dividends. Here's how you can earn $500 monthly from Eli Lilly. 
Via Benzinga
Is It Too Late to Buy Novo Nordisk Stock After Its 57% Surge?
Novo Nordisk stock has surged thanks to booming sales of Ozempic and Wegovy. 
Via The Motley Fool
Novo Nordisk Tumbles 3% In Wednesday Premarket: What's Causing 'Miracle' Weight Loss Drug Ozempic Maker's Stock Slide?
The dip in Novo Nordisk's shares comes despite deep-pocketed investors were adopting a bullish approach. 
Via Benzinga
Prediction: This Will Be the Best Pharmaceutical Stock to Own Over the Next 10 Years
Eli Lilly is one of the most innovative pharmaceutical companies right now. 
Via The Motley Fool
Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
EQNX::TICKER_START (NYSE:ANVS),(NYSE:PFE),(NYSE:LLY),(NYSE:GSK),(NYSE:NVO) EQNX::TICKER_END 
Via FinancialNewsMedia
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
From FN Media Group LLC
Via GlobeNewswire
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
These tried-and-true businesses can deliver returns to investors for many years to come. 
Via The Motley Fool
Large Cap Biopharma And Healthcare, A Port In A Storm
Healthcare and biopharma show nice gains in a volatile week. 
Via Talk Markets
Eli Lilly's Zepbound Challenges Novo Nordisk's Wegovy Amid Supply Issues
Eli Lilly's Zepbound and Novo Nordisk's Wegovy face supply shortages, influencing doctors' prescribing habits. Both companies are investing heavily to meet demand in the lucrative U.S. market. 
Via Benzinga
After Ozempic And Botox, Hollywood Is Going Gaga Over This New Anti-Aging Supplement
This trend is gaining momentum although its effectiveness is yet to be determined. 
Via Benzinga
THQ: A Favorite Pharma Fund
Medical spending is set to rise as an increasing proportion of the US population crosses the retirement age. Spending is projected to grow an average of 5.6% a year through 2032. The abrdn Healthcare... 
Via Talk Markets
Topics Retirement
Exposures Pension
These 2 Simple ETFs Could Turn $500 a Month Into $1 Million.
Learn how $500 a month can grow into a sizable nest egg. 
Via The Motley Fool
Topics ETFs
Eli Lilly's Obesity Drug Shows a Heart Benefit. Is It Time to Buy?
Recent results from a clinical trial show that treatment with Zepbound significantly reduced patients' risk of heart failure outcomes, including cardiovascular death. 
Via The Motley Fool
3 Unstoppable Stocks to Buy in August
It's not hard to envision how all three of these stocks can deliver exceptional growth. 
Via The Motley Fool
Eli Lilly vs Novo Nordisk: A Recent Study Suggests This Company Has the Best Weight Loss Drug
These healthcare stocks are up more than 400% in the past five years, thanks to their dominance in the anti-obesity market. 
Via The Motley Fool
Is This Decision by Pfizer Bad News for Eli Lilly?
Lilly's revenue gains have helped its stock to roar higher. 
Via The Motley Fool
Using Weight Loss Medications Such As Wegovy, Zepbound? Psychologist Warns Of Linked Eating Disorder Risks
Psychologists warn of increased eating disorders linked to popular GLP-1 weight loss drugs like Wegovy and Zepbound. Experts urge better screening and research to address potential risks. 
Via Benzinga
ResMed Earnings Reflect Increased Demand For Sleep Devices, Performance Indicates Positive Dynamics, Opportunities
ResMed reported Q4 2024 revenue of $1.22 billion, driven by strong demand for sleep devices and software services. Gross margin improved significantly due to reduced costs and higher selling prices.... 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.